Bausch Health call volume above normal and directionally bullish — Oct 19th, 2024

https://www.tipranks.com/news/the-fly/bausch-health-call-volume-above-normal-and-directionally-bullish-19 Bullish option flow detected in Bausch Health (BHC) with 5,026 calls trading, 2x expected, and implied vol increasing over 2 points to 76.97%. Jan-25 10 calls and 10/25 weekly 9 calls...

Bausch + Lomb Receives FDA Approval for enVista® Envy™ Full Range of Vision Intraocular Lens — Oct 14th, 2024

VAUGHAN, Ontario, October 14, 2024--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that the U.S. Food and Drug Administration has approved the enVista® Envy™ full ran...

Bausch Health call volume above normal and directionally bullish — Oct 19th, 2024

https://www.tipranks.com/news/the-fly/bausch-health-call-volume-above-normal-and-directionally-bullish-19 Bullish option flow detected in Bausch Health (BHC) with 5,026 calls trading, 2x expected, and implied vol increasing over 2 points to 76.97%. Jan-25 10 calls and 10/25 weekly 9 calls...

Bausch + Lomb price target raised to $19 from $17 at Evercore ISI — Oct 2nd, 2024

Evercore ISI raised the firm’s price target on Bausch + Lomb to $19 from $17 and keeps an In Line rating on the shares. In MedTech, utilization remains positive into Q3 and the capex outlook into the next year remains “healthy,” says Evercore. In life science tools, bioprocess trends...

Bausch Health call volume above normal and directionally bullish — Oct 19th, 2024

https://www.tipranks.com/news/the-fly/bausch-health-call-volume-above-normal-and-directionally-bullish-19 Bullish option flow detected in Bausch Health (BHC) with 5,026 calls trading, 2x expected, and implied vol increasing over 2 points to 76.97%. Jan-25 10 calls and 10/25 weekly 9 calls...

Bausch Health call volume above normal and directionally bullish — Oct 19th, 2024

https://www.tipranks.com/news/the-fly/bausch-health-call-volume-above-normal-and-directionally-bullish-19 Bullish option flow detected in Bausch Health (BHC) with 5,026 calls trading, 2x expected, and implied vol increasing over 2 points to 76.97%. Jan-25 10 calls and 10/25 weekly 9 calls...

Bausch Health call volume above normal and directionally bullish — Oct 19th, 2024

https://www.tipranks.com/news/the-fly/bausch-health-call-volume-above-normal-and-directionally-bullish-19 Bullish option flow detected in Bausch Health (BHC) with 5,026 calls trading, 2x expected, and implied vol increasing over 2 points to 76.97%. Jan-25 10 calls and 10/25 weekly 9 calls...

Bausch + Lomb price target raised to $19 from $17 at Evercore ISI — Oct 2nd, 2024

Evercore ISI raised the firm’s price target on Bausch + Lomb to $19 from $17 and keeps an In Line rating on the shares. In MedTech, utilization remains positive into Q3 and the capex outlook into the next year remains “healthy,” says Evercore. In life science tools, bioprocess trends...

Bausch + Lomb Receives FDA Approval for enVista® Envy™ Full Range of Vision Intraocular Lens — Oct 14th, 2024

VAUGHAN, Ontario, October 14, 2024--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that the U.S. Food and Drug Administration has approved the enVista® Envy™ full ran...

Bausch Health call volume above normal and directionally bullish — Oct 19th, 2024

https://www.tipranks.com/news/the-fly/bausch-health-call-volume-above-normal-and-directionally-bullish-19 Bullish option flow detected in Bausch Health (BHC) with 5,026 calls trading, 2x expected, and implied vol increasing over 2 points to 76.97%. Jan-25 10 calls and 10/25 weekly 9 calls...

Bausch + Lomb price target raised to $19 from $17 at Evercore ISI — Oct 2nd, 2024

Evercore ISI raised the firm’s price target on Bausch + Lomb to $19 from $17 and keeps an In Line rating on the shares. In MedTech, utilization remains positive into Q3 and the capex outlook into the next year remains “healthy,” says Evercore. In life science tools, bioprocess trends...

Bausch Health call volume above normal and directionally bullish — Oct 19th, 2024

https://www.tipranks.com/news/the-fly/bausch-health-call-volume-above-normal-and-directionally-bullish-19 Bullish option flow detected in Bausch Health (BHC) with 5,026 calls trading, 2x expected, and implied vol increasing over 2 points to 76.97%. Jan-25 10 calls and 10/25 weekly 9 calls...

Bausch Health call volume above normal and directionally bullish — Oct 19th, 2024

https://www.tipranks.com/news/the-fly/bausch-health-call-volume-above-normal-and-directionally-bullish-19 Bullish option flow detected in Bausch Health (BHC) with 5,026 calls trading, 2x expected, and implied vol increasing over 2 points to 76.97%. Jan-25 10 calls and 10/25 weekly 9 calls...

Bausch Health call volume above normal and directionally bullish — Oct 19th, 2024

https://www.tipranks.com/news/the-fly/bausch-health-call-volume-above-normal-and-directionally-bullish-19 Bullish option flow detected in Bausch Health (BHC) with 5,026 calls trading, 2x expected, and implied vol increasing over 2 points to 76.97%. Jan-25 10 calls and 10/25 weekly 9 calls...

Bausch + Lomb Launches Opal™ Digital Marketplace in the United States — Oct 1st, 2024

VAUGHAN, Ontario, October 01, 2024--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. launch of Opal, a digital e-commerce marketplace. Designed to help maximize e...

Bausch Health call volume above normal and directionally bullish — Oct 19th, 2024

https://www.tipranks.com/news/the-fly/bausch-health-call-volume-above-normal-and-directionally-bullish-19 Bullish option flow detected in Bausch Health (BHC) with 5,026 calls trading, 2x expected, and implied vol increasing over 2 points to 76.97%. Jan-25 10 calls and 10/25 weekly 9 calls...

Bausch + Lomb Launches Opal™ Digital Marketplace in the United States — Oct 1st, 2024

VAUGHAN, Ontario, October 01, 2024--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. launch of Opal, a digital e-commerce marketplace. Designed to help maximize e...

Bausch + Lomb Will Release Third-Quarter 2024 Financial Results on October 30 — Oct 9th, 2024

VAUGHAN, Ontario, October 09, 2024--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its third-quarter 2024 financial results on Wednesday, October 30, 2024. Bausch + Lomb wi...

Bausch + Lomb price target raised to $19 from $17 at Evercore ISI — Oct 2nd, 2024

Evercore ISI raised the firm’s price target on Bausch + Lomb to $19 from $17 and keeps an In Line rating on the shares. In MedTech, utilization remains positive into Q3 and the capex outlook into the next year remains “healthy,” says Evercore. In life science tools, bioprocess trends...

Bausch + Lomb Will Release Third-Quarter 2024 Financial Results on October 30 — Oct 9th, 2024

VAUGHAN, Ontario, October 09, 2024--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its third-quarter 2024 financial results on Wednesday, October 30, 2024. Bausch + Lomb wi...

Bausch + Lomb Receives FDA Approval for enVista® Envy™ Full Range of Vision Intraocular Lens — Oct 14th, 2024

VAUGHAN, Ontario, October 14, 2024--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that the U.S. Food and Drug Administration has approved the enVista® Envy™ full ran...

Bausch + Lomb price target raised to $19 from $17 at Evercore ISI — Oct 2nd, 2024

Evercore ISI raised the firm’s price target on Bausch + Lomb to $19 from $17 and keeps an In Line rating on the shares. In MedTech, utilization remains positive into Q3 and the capex outlook into the next year remains “healthy,” says Evercore. In life science tools, bioprocess trends...

Bausch + Lomb price target raised to $19 from $17 at Evercore ISI — Oct 2nd, 2024

Evercore ISI raised the firm’s price target on Bausch + Lomb to $19 from $17 and keeps an In Line rating on the shares. In MedTech, utilization remains positive into Q3 and the capex outlook into the next year remains “healthy,” says Evercore. In life science tools, bioprocess trends...

Bausch + Lomb Will Release Third-Quarter 2024 Financial Results on October 30 — Oct 9th, 2024

VAUGHAN, Ontario, October 09, 2024--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its third-quarter 2024 financial results on Wednesday, October 30, 2024. Bausch + Lomb wi...

Bausch + Lomb Will Release Third-Quarter 2024 Financial Results on October 30 — Oct 9th, 2024

VAUGHAN, Ontario, October 09, 2024--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its third-quarter 2024 financial results on Wednesday, October 30, 2024. Bausch + Lomb wi...

Bausch + Lomb Receives FDA Approval for enVista® Envy™ Full Range of Vision Intraocular Lens — Oct 14th, 2024

VAUGHAN, Ontario, October 14, 2024--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that the U.S. Food and Drug Administration has approved the enVista® Envy™ full ran...

Bausch + Lomb Launches Opal™ Digital Marketplace in the United States — Oct 1st, 2024

VAUGHAN, Ontario, October 01, 2024--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. launch of Opal, a digital e-commerce marketplace. Designed to help maximize e...

Bausch + Lomb Will Release Third-Quarter 2024 Financial Results on October 30 — Oct 9th, 2024

VAUGHAN, Ontario, October 09, 2024--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its third-quarter 2024 financial results on Wednesday, October 30, 2024. Bausch + Lomb wi...

Bausch Health call volume above normal and directionally bullish — Oct 19th, 2024

https://www.tipranks.com/news/the-fly/bausch-health-call-volume-above-normal-and-directionally-bullish-19 Bullish option flow detected in Bausch Health (BHC) with 5,026 calls trading, 2x expected, and implied vol increasing over 2 points to 76.97%. Jan-25 10 calls and 10/25 weekly 9 calls...

Bausch + Lomb Will Release Third-Quarter 2024 Financial Results on October 30 — Oct 9th, 2024

VAUGHAN, Ontario, October 09, 2024--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its third-quarter 2024 financial results on Wednesday, October 30, 2024. Bausch + Lomb wi...

Bausch + Lomb Will Release Third-Quarter 2024 Financial Results on October 30 — Oct 9th, 2024

VAUGHAN, Ontario, October 09, 2024--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its third-quarter 2024 financial results on Wednesday, October 30, 2024. Bausch + Lomb wi...

Bausch + Lomb Launches Opal™ Digital Marketplace in the United States — Oct 1st, 2024

VAUGHAN, Ontario, October 01, 2024--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. launch of Opal, a digital e-commerce marketplace. Designed to help maximize e...

Bausch + Lomb Launches Opal™ Digital Marketplace in the United States — Oct 1st, 2024

VAUGHAN, Ontario, October 01, 2024--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. launch of Opal, a digital e-commerce marketplace. Designed to help maximize e...

Bausch + Lomb Receives FDA Approval for enVista® Envy™ Full Range of Vision Intraocular Lens — Oct 14th, 2024

VAUGHAN, Ontario, October 14, 2024--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that the U.S. Food and Drug Administration has approved the enVista® Envy™ full ran...

Bausch + Lomb Launches Opal™ Digital Marketplace in the United States — Oct 1st, 2024

VAUGHAN, Ontario, October 01, 2024--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. launch of Opal, a digital e-commerce marketplace. Designed to help maximize e...

Bausch + Lomb Launches Opal™ Digital Marketplace in the United States — Oct 1st, 2024

VAUGHAN, Ontario, October 01, 2024--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. launch of Opal, a digital e-commerce marketplace. Designed to help maximize e...

Bausch + Lomb price target raised to $19 from $17 at Evercore ISI — Oct 2nd, 2024

Evercore ISI raised the firm’s price target on Bausch + Lomb to $19 from $17 and keeps an In Line rating on the shares. In MedTech, utilization remains positive into Q3 and the capex outlook into the next year remains “healthy,” says Evercore. In life science tools, bioprocess trends...

Bausch + Lomb Will Release Third-Quarter 2024 Financial Results on October 30 — Oct 9th, 2024

VAUGHAN, Ontario, October 09, 2024--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its third-quarter 2024 financial results on Wednesday, October 30, 2024. Bausch + Lomb wi...

Bausch + Lomb Receives FDA Approval for enVista® Envy™ Full Range of Vision Intraocular Lens — Oct 14th, 2024

VAUGHAN, Ontario, October 14, 2024--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that the U.S. Food and Drug Administration has approved the enVista® Envy™ full ran...

Bausch + Lomb price target raised to $19 from $17 at Evercore ISI — Oct 2nd, 2024

Evercore ISI raised the firm’s price target on Bausch + Lomb to $19 from $17 and keeps an In Line rating on the shares. In MedTech, utilization remains positive into Q3 and the capex outlook into the next year remains “healthy,” says Evercore. In life science tools, bioprocess trends...

Bausch + Lomb Launches Opal™ Digital Marketplace in the United States — Oct 1st, 2024

VAUGHAN, Ontario, October 01, 2024--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. launch of Opal, a digital e-commerce marketplace. Designed to help maximize e...

Bausch + Lomb Receives FDA Approval for enVista® Envy™ Full Range of Vision Intraocular Lens — Oct 14th, 2024

VAUGHAN, Ontario, October 14, 2024--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that the U.S. Food and Drug Administration has approved the enVista® Envy™ full ran...

Bausch + Lomb price target raised to $19 from $17 at Evercore ISI — Oct 2nd, 2024

Evercore ISI raised the firm’s price target on Bausch + Lomb to $19 from $17 and keeps an In Line rating on the shares. In MedTech, utilization remains positive into Q3 and the capex outlook into the next year remains “healthy,” says Evercore. In life science tools, bioprocess trends...

Bausch + Lomb Receives FDA Approval for enVista® Envy™ Full Range of Vision Intraocular Lens — Oct 14th, 2024

VAUGHAN, Ontario, October 14, 2024--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that the U.S. Food and Drug Administration has approved the enVista® Envy™ full ran...